As per the extended contract, the company will develop a controlled release formulation that combines the client’s optimized product candidate with their proprietary drug delivery technology, PolyActive.
If the project is successful, the contract may advance to a full process development and manufacturing contract, and a licensing agreement, the company said.
The studies conducted by OctoPlus for previous compounds of the client and pre-clinical studies performed with the prototype controlled release formulation were also successful.